Indication: Non-Small Cell Lung Cancer (NSCLC)

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer

Patients with PD-L1 high status

Sub-indication: High PD-L1 Metastatic NSCLC

Line of Therapy: 1st line metastatic NSCLC

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: EMD Serono, Inc

Learn more at ClinicalTrials.gov

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.